$1.62
2.75% day before yesterday
Nasdaq, Dec 27, 10:00 pm CET
ISIN
KYG108301006
Symbol
BYSI
Sector
Industry

BeyondSpring Inc. Stock price

$1.62
-0.28 14.55% 1M
-0.85 34.35% 6M
+0.72 79.44% YTD
+0.73 81.46% 1Y
-2.89 64.11% 3Y
-14.26 89.82% 5Y
-15.19 90.39% 10Y
Nasdaq, Closing price Fri, Dec 27 2024
-0.05 2.75%
ISIN
KYG108301006
Symbol
BYSI
Sector
Industry

Key metrics

Market capitalization $65.09m
Enterprise Value $58.33m
P/E (TTM) P/E ratio negative
EV/Sales (TTM) EV/Sales 31.03
P/S ratio (TTM) P/S ratio 34.62
P/B ratio (TTM) P/B ratio negative
Revenue (TTM) Revenue $1.88m
EBIT (operating result TTM) EBIT $-17.05m
EPS (TTM) EPS $-0.40
Short interest 8.33%
Show more

Is BeyondSpring Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.

BeyondSpring Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

1 Analyst has issued a forecast BeyondSpring Inc.:

1x Buy
100%

Analyst Opinions

1 Analyst has issued a forecast BeyondSpring Inc.:

Buy
100%

Financial data from BeyondSpring Inc.

Income Statement P&L | Balance Sheet | Cash Flow


TTM Annually
Jun '24
+/-
%
1.88 1.88
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 9.36 9.36
-
498%
- Research and Development Expense 9.57 9.57
-
509%
- -
-
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT -17 -17
74% 74%
-907%
Net Profit -16 -16
-
-828%

In millions USD.

Don't miss a Thing! We will send you all news about BeyondSpring Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

BeyondSpring Inc. Stock News

Neutral
GlobeNewsWire
about 2 months ago
In 30 metastatic NSCLC patients who progressed on PD-1/PD-L1 inhibitors, the triple IO combo regimen at median follow-up time of 11.5 months achieved a DCR of 89.3% and Median PFS of 8.6 months In 30 metastatic NSCLC patients who progressed on PD-1/PD-L1 inhibitors, the triple IO combo regimen at median follow-up time of 11.5 months achieved a DCR of 89.3% and Median PFS of 8.6 months
Positive
GuruFocus
3 months ago
BeyondSpring Inc. (BYSI, Financial) experienced a notable stock price increase of 5.39%, reaching $2.54 per share. The trading volume was 20,920 shares, with a turnover rate of 0.05% and a volatility of 10.37%.
Neutral
GlobeNewsWire
3 months ago
Plinabulin/Docetaxel Combination Demonstrated Favorable Benefit/Risk Ratio over Docetaxel Alone: Significant Improvement in Overall Survival, Progression Free Survival, and Objective Response, with additional Significant Reduction of Grade 4 Neutropenia (>80% relative reduction), and Improved Patients' Quality of Life Plinabulin/Docetaxel Combination Demonstrated Favorable Benefit/Risk Ratio ov...
More BeyondSpring Inc. News

Company Profile

BeyondSpring, Inc. is a clinical stage company, which engages in the development of cancer therapies. It focuses on non-small cell lung cancer, neutropenia prevention, and plinabulin and nivolumab. The company was founded by Lan Huang and Lin Qing Jia in 2013 and is headquartered in New York, NY.

Head office Cayman Islands
CEO Lan Huang
Employees 35
Founded 2010
Website www.beyondspringpharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today